AKTX.O (AKTX.O) News
Follow AKTX.O (AKTX.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Akari Therapeutics grants director Bazemore restricted stock units in lieu of unpaid cash retainers
Akari Therapeutics granted director Robert B. Bazemore stock options covering 60,000 American Depositary Shares on August 18, 2026. Bazemore also received grants of 13,100 American Depositary Shares on August 18, 2026, a
REGULATION | Oct 16, 2026, 09:22 PM UTC
L
Akari Therapeutics Targets Mid — 2027 Start for AKTX — 101 Phase 1 Trial
Akari Therapeutics is advancing AKTX-101 through preclinical safety studies and manufacturing, targeting Phase 1 clinical development in mid-2027. Its PH1 payload is designed to disrupt RNA splicing in cancer cells, offe
NEWS | Oct 15, 2026, 01:22 PM UTC
L
Akari Therapeutics appoints Vatnak Vat — Ho chief business officer
Akari Therapeutics named Vatnak Vat-Ho chief business officer to lead corporate strategy, partnering, licensing, investor engagement. Vat-Ho brings 20+ years in oncology business development, biopharma strategy, equity r
NEWS | Oct 13, 2026, 01:07 PM UTC